Researchers have found that patients with stage B heart failure characteristics and type 2 diabetes have impaired functional capacity.

Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.

Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development ...

Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice ...